According to the International Myeloma Foundation (IMF), CEP-18770, a boronic-acid based compound, is currently being developed by the drug company Cephalon. The new drug is expected to have a number of different applications and work against several different types of cancer, including multiple myeloma. Animal studies showed CEP-18770 to be superior to Velcade, both in effectiveness and reduced side-effects. Phase II studies should begin by the end of this year.
Feel good, keep smiling and keep the faith! More new drugs like CEP-18770 are being tested each month. Pat